carboplatin + paclitaxel + dostarlimab + bevacizumab

**carboplatin + paclitaxel + dostarlimab + bevacizumab** is an investigational four-drug **combination regimen** for advanced or recurrent gynecologic cancers, mainly explored in endometrial cancer and ovarian cancer. - **Carboplatin** is a platinum-based chemotherapeutic agent causing DNA crosslinking and apoptosis in rapidly dividing cells. - **Paclitaxel** is a microtubule inhibitor that prevents cell division by stabilizing microtubule polymers. - **Dostarlimab** is a monoclonal antibody and immune checkpoint inhibitor targeting PD-1 (programmed cell death protein 1), enhancing T-cell-mediated anti-tumor immunity[4][8]. - **Bevacizumab** is a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis and tumor blood vessel formation. The combination aims to leverage **cytotoxic chemotherapy**, **immune checkpoint inhibition**, and **anti-angiogenesis** for improved disease control. Clinical protocols often use intravenous administration, with chemotherapy cycles alongside dostarlimab and subsequent dostarlimab monotherapy in maintenance phases[6]. Recent and ongoing clinical trials assess this combination for advanced endometrial cancer and platinum-resistant ovarian cancer[1][3][4][6][8].